Letters to the editor

  • L. Tax
  • U. Täuber


Testosterone Absolute Bioavailability Testosterone Replacement Therapy Testosterone Undecanoate Androgen Replacement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Bancroft J., Wu FCW. Changes in erectile responsiveness during androgen replacement therapy. Arch. Sex. Behav. 1983;12: 59–66.CrossRefPubMedGoogle Scholar
  2. 2.
    Della Casa L., Grandi M., Carani C, Sighinolfi R. Effects of oral testosterone undecanoate therapy in andrological pathology. In: Therapy in andrology; Pharmacological, surgical and psychological aspects; proceedings of an international congres, Pisa, June 21–24, 1982. Amsterdam: Exc. Med. 1982; 78–86.Google Scholar
  3. 3.
    Franchi F., Luisi M., Kicovic PM. Long-term study of oral testosterone undecanoate in hypogonadal males. Int. J. Androl. 1978a;1; 270–8.CrossRefGoogle Scholar
  4. 4.
    Franchimont P., Kicovic PM., Mattei A., Roulier R. Effects of oral testosterone undecanoate in hypogonadal male patients. Clin Endocrinol (Oxf.) 1978;9: 313–20.CrossRefGoogle Scholar
  5. 5.
    Franchimont P., Kicovic PM., Mattei A., Roulier R. Treatment of hypogonadism with testosterone undecanoate. In: International congress on therapy in andrology; Pharmacological, surgical and psychological aspects; Pisa, June 21–24, 1982. Pisa: Z Uitg 1982; 15.Google Scholar
  6. 6.
    Geere G., Jones J., Atherden SM., Grant D. Plasma androgens after a single dose of testosterone undecanoate. Arch. Dis. Child. 1980;55: 218–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Gooren LJG. Long-term safety of the oral androgen testosterone undecanoate. Int. J. Androl. 1986;9: 21–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Hirschhäuser C, Hopkinson CRN, Sturm G., Coert A. Testosterone undecanoate: a new orally active androgen. Acta Endocrinol (Copenh) 1975;80: 179–87.Google Scholar
  9. 9.
    Luisi M., Franchi F. Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. J. Endocrinol Invest 1980;3: 305–8.Google Scholar
  10. 10.
    Maisey NM., Bingham J., Marks V., English J., Chakraborty J. Clinical efficacy of testosterone undecanoate in male hypogonadism. Clin. Endocrinol (Oxf.) 1981;14: 625–9.CrossRefGoogle Scholar
  11. 11.
    O’Carroll R., Shapiro C, Bancroft J. Androgens, behaviour and nocturnal erections in hypogonadal men; the effects of varying the replacement dose. Clin. Endocrinol (Oxf.) 1985;23: 517–38.CrossRefGoogle Scholar
  12. 12.
    Skakkebaek NE., Bancroft J., Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf.) 1981;14: 49–61.CrossRefGoogle Scholar
  13. 13.
    Weil J., Bidlingmaier F., Butenandt O., Sippell WG, Baumgartner W., Knorr D. Treatment of anorchia with oral testosterone undecanoate: pharmacodynamics and clinical effectiveness. Acta Endocrinol (Copenh.) 1980;95: 244–50.Google Scholar
  14. 14.
    Wu FCW, Bancroft J., Davidson DW., Nicol K. The behavioural effects of testosterone undecanoate in adult men with Klinefelter’s syndrome: a controlled study. Clin Endocrinol (Oxf.) 1982;16: 489–97.CrossRefGoogle Scholar


  1. 1.
    Cantrill I.A., Dewis P., Large D.M., Newman M. and Anderson D.C. (1984): Which testosterone replacement therapy? Clin. Endocrin.21, 97–107.CrossRefGoogle Scholar
  2. 2.
    Frey H., Aakwaag A., Saanum D. and Falich J. (1979): Bioavailability of oral testosterone in males. Eur. J. Clin. Pharmacol.16, 345–349.CrossRefPubMedGoogle Scholar
  3. 3.
    Southren A.K., Cordon G.G., Tochimoto S., Pinzon G., Lane D.R. and Stypulkowski W. (1967): Mean plasma concentration, metabolic clearance and basal plasma production rates of testosterone in normal Young men and women using a constant infusion procedure: Effect of time of day and plasma concentration on the metabolic clearance rate of testosterone. J. Clin. Endocr.27, 686–694.CrossRefPubMedGoogle Scholar
  4. 4.
    Täuber U., Schröder K., Düsterberg B. and Matthes H. (1986): Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone Europ. J. of Drug Metab. and Pharmacokin. Vol. 11, No 2, pp. 145–149.Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • L. Tax
    • 1
  • U. Täuber
    • 2
  1. 1.OrganonHolland
  2. 2.ScheringBerlin

Personalised recommendations